Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41467-021-25175-5
DC FieldValue
dc.titleThe MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
dc.contributor.authorRisbridger, Gail P.
dc.contributor.authorClark, Ashlee K.
dc.contributor.authorPorter, Laura H.
dc.contributor.authorToivanen, Roxanne
dc.contributor.authorBakshi, Andrew
dc.contributor.authorLister, Natalie L.
dc.contributor.authorPook, David
dc.contributor.authorPezaro, Carmel J.
dc.contributor.authorSandhu, Shahneen
dc.contributor.authorKeerthikumar, Shivakumar
dc.contributor.authorQuezada Urban, Rosalia
dc.contributor.authorPapargiris, Melissa
dc.contributor.authorKraska, Jenna
dc.contributor.authorMadsen, Heather B.
dc.contributor.authorWang, Hong
dc.contributor.authorRichards, Michelle G.
dc.contributor.authorNiranjan, Birunthi
dc.contributor.authorO’Dea, Samantha
dc.contributor.authorTeng, Linda
dc.contributor.authorWheelahan, William
dc.contributor.authorLi, Zhuoer
dc.contributor.authorChoo, Nicholas
dc.contributor.authorOuyang, John F.
dc.contributor.authorThorne, Heather
dc.contributor.authorDevereux, Lisa
dc.contributor.authorHicks, Rodney J.
dc.contributor.authorSengupta, Shomik
dc.contributor.authorHarewood, Laurence
dc.contributor.authorIddawala, Mahesh
dc.contributor.authorAzad, Arun A.
dc.contributor.authorGoad, Jeremy
dc.contributor.authorGrummet, Jeremy
dc.contributor.authorKourambas, John
dc.contributor.authorKwan, Edmond M.
dc.contributor.authorMoon, Daniel
dc.contributor.authorMurphy, Declan G.
dc.contributor.authorPedersen, John
dc.contributor.authorClouston, David
dc.contributor.authorNorden, Sam
dc.contributor.authorRyan, Andrew
dc.contributor.authorFuric, Luc
dc.contributor.authorGoode, David L.
dc.contributor.authorFrydenberg, Mark
dc.contributor.authorLawrence, Mitchell G.
dc.contributor.authorTaylor, Renea A.
dc.date.accessioned2022-10-13T06:43:43Z
dc.date.available2022-10-13T06:43:43Z
dc.date.issued2021-08-19
dc.identifier.citationRisbridger, Gail P., Clark, Ashlee K., Porter, Laura H., Toivanen, Roxanne, Bakshi, Andrew, Lister, Natalie L., Pook, David, Pezaro, Carmel J., Sandhu, Shahneen, Keerthikumar, Shivakumar, Quezada Urban, Rosalia, Papargiris, Melissa, Kraska, Jenna, Madsen, Heather B., Wang, Hong, Richards, Michelle G., Niranjan, Birunthi, O’Dea, Samantha, Teng, Linda, Wheelahan, William, Li, Zhuoer, Choo, Nicholas, Ouyang, John F., Thorne, Heather, Devereux, Lisa, Hicks, Rodney J., Sengupta, Shomik, Harewood, Laurence, Iddawala, Mahesh, Azad, Arun A., Goad, Jeremy, Grummet, Jeremy, Kourambas, John, Kwan, Edmond M., Moon, Daniel, Murphy, Declan G., Pedersen, John, Clouston, David, Norden, Sam, Ryan, Andrew, Furic, Luc, Goode, David L., Frydenberg, Mark, Lawrence, Mitchell G., Taylor, Renea A. (2021-08-19). The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications 12 (1) : 5049. ScholarBank@NUS Repository. https://doi.org/10.1038/s41467-021-25175-5
dc.identifier.issn2041-1723
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233034
dc.description.abstractPreclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012–2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer. © 2021, The Author(s).
dc.publisherNature Research
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/s41467-021-25175-5
dc.description.sourcetitleNature Communications
dc.description.volume12
dc.description.issue1
dc.description.page5049
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41467-021-25175-5.pdf4.68 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons